Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benzethonium→

Benzethonium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10172-60-8
Molecular formula
C27H42NO2+
Molecular weight
412.6 g/mol
Drug class
Quaternary ammonium antisepticcationic surfactant
Mechanism of action
Adsorbs to microbial cell membranes and disrupts membrane integrity, leading to leakage of intracellular contents and loss of microbial viability. It is primarily a local antiseptic and is not intended for systemic administration.
Indications / reported uses
  • Topical cleansing and antisepsis of minor skin wounds in authorised OTC preparations
  • Use as an antimicrobial preservative or antiseptic excipient in selected products; exact claims depend on formulation and jurisdiction

Sources: US eCFR — Skin antiseptic drug products · PubChem — Benzethonium chloride · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benzethonium Environmental Risk Assessment (ERA) (the Benzethonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.